Gossamer Bio, Inc. (Nasdaq: GOSS) announced its financial results for the fourth quarter and full year ended December 31, 2025, revealing a net loss of $47.2 million for Q4 and $170.4 million for the full year. The company reported cash, cash equivalents, and marketable securities totaling $137 million at year-end 2025. Following the PROSERA Phase 3 topline results, which narrowly missed the prespecified statistical threshold for its primary endpoint, Gossamer is focusing on evaluating the totality of the dataset and engaging with the FDA to assess strategic options and capital allocation. Enrollment in the Phase 3 SERANATA Study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) has been paused as the company evaluates the implications of the PROSERA results. Additionally, Gossamer has implemented a reduction in force to align resources with near-term priorities. The company continues to conduct additional analyses of the PROSERA dataset and plans to request a Type C meeting with the FDA to discuss potential regulatory paths forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.